E7080 (Lenvatinib)

Catalog No. A10340

E7080 (Lenvatinib)是一种多激酶抑制剂,可同时抑制VEGFR2和VEGFR3激酶。
  • Mai Nakahara, .et al. Effect of Lenvatinib treatment on the cell cycle and microRNA profile in hepatocellular carcinoma cells, Biomed Rep, 2022, Aug 3;17(4):78 PMID: 36158319
  • Paula Sagmeister, .et al. Comparative Response of HCC Cells to TKIs: Modified in vitro Testing and Descriptive Expression Analysis, J Hepatocell Carcinoma, 2022, Jul 9;9:595-607 PMID: 35845819
  • Aya Hasan Alshammari, .et al. Discrimination of hand-foot skin reaction caused by tyrosine kinase inhibitors based on direct keratinocyte toxicity and vascular endothelial growth factor receptor-2 inhibition, Biochem Pharmacol, 2022, Mar;197:114914 PMID: 35041812
  • Keisuke Enomoto, .et al. Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models, Cancers (Basel), 2021, Feb 18;13(4):862 PMID: 33670725
  • Jindal A, .et al. Milciclib and sorafenib synergistically downregulate c-Myc to suppress tumor growth in an orthotopic murine model of human hepatocellular carcinoma, J Transl Sci, 2020, 7: 1-10
  • Koide H, .et al. Substrate-dependent effects of molecular-targeted anticancer agents on activity of organic anion transporting polypeptide 1B1, Xenobiotica, 2018, Oct;48(10):1059-1071 PMID: 29034773
  • Fujita KI, .et al. Involvement of the Transporters P-Glycoprotein and Breast Cancer Resistance Protein in Dermal Distribution of the Multikinase Inhibitor Regorafenib and Its Active Metabolites, J Pharm Sci, 2017, Sep;106(9):2632-2641 PMID: 28479358
  • Tomoko Ogawa-Morita, .et al. Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma, Int J Anal Chem, 2017, 2017: 2341876 PMID: 28680445
Catalog Num A10340
M. Wt 426.9
Formula C21H19ClN4O4
Purity >98%
Storage at -20°C 3 years Powder
CAS No. 417716-92-8
Synonyms E-7080
SMILES COC1=CC2=NC=CC(=C2C=C1C(=O)N)OC3=CC(=C(C=C3)NC(=O)NC4CC4)Cl
E7080 (Lenvatinib)是一种多激酶抑制剂,可同时抑制VEGFR2和VEGFR3激酶。
Targets
Target Value
VEGFR2/KDRIC50: 4.0nM
VEGFR3/FLT4IC50: 5.2nM
VEGFR1/FLT1IC50: 22nM
PDGFRβIC50: 39nM
FGFR1IC50: 46nM
PDGFRαIC50: 51nM
KitIC50: 100nM
EphB4IC50: >10μM
IGF-1RIC50: >10μM
Insulin ReceptorIC50: >10μM
SrcIC50: >10μM
Akt1IC50: >10μM
CDK4/CyclinDIC50: >10μM
PLK1IC50: >10μM
FAKIC50: >10μM
PKCαIC50: >10μM
In vitro (25°C) DMSO Warmed: 35 mg/mL (81.99 mM)
Water Insoluble
Ethanol Insoluble
In vivo 0.5% methylcellulose 28 mg/mL
* <1 mg/ml means slightly soluble or insoluble.
* Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
0.1 mM 23.42 mL 117.12 mL 234.25 mL
0.5 mM 4.68 mL 23.42 mL 46.85 mL
1 mM 2.34 mL 11.71 mL 23.42 mL
5 mM 0.47 mL 2.34 mL 4.68 mL

*The above data is based on the productmolecular weight 426.9. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.